A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children

Journal of Acquired Immune Deficiency Syndromes

Volumn 40, Issue 4, 2005, Pages 448-450

  Giacomet, Vania ^a   Mora, Stefano ^b   Martelli, Laura ^a   Merlo, Marzia ^a   Sciannamblo, Mariateresa ^b   Viganò, Alessandra ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Bone mineral content; HIV infected children; Tenofovir

Indexed keywords

TENOFOVIR;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUMBAR SPINE; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADENINE; ADOLESCENT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BONE DENSITY; CHILD; DENSITOMETRY, X-RAY; HIV INFECTIONS; HUMANS; PHOSPHONIC ACIDS; STAVUDINE;

EID: 27944475515     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000184860.62189.c8     Document Type: Article

References (8)

1. Viganò A, Mora S. Adverse effects of antiretroviral therapy: focus on bone density. Expert Opin Drug Saf. 2004;3:199-208.
2. Gallant JE, Staszeswski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients. A 3-year randomized trial. JAMA. 2004;292:191-201.
3. Powderly W, Cohen C, Gallant J, et al. Similar incidence of osteopenia and osteoporosis in ART-naïve patients treated with tenofovir DF or stavudine in combination with lamivudine or efavirenz over 144 weeks [abstract 823]. Presented at: 12th Conference on Retrovirus and Opportunistic Infections; 2005; Boston.
4. Hazra R, Gafni R, Maldarelli F, et al. Safety, tolerability, clinical responses to tenofovir DF in combination with other antiretrovirals in heavily treatment-experienced HIV-infected children: data through 48 weeks [abstract 928]. Presented at: 11th Conference on Retrovirus and Opportunistic Infections; 2004; San Francisco.
5. Ramos JT, Gonzales Tome MI, Rojo P, et al. Experience with tenofovir disoproxil fumarate (TDF) in heavily pretreated HIV-infected children [abstract TuPeB4465]. Presented at: 15th International AIDS Conference; 2004; Bangkok.
6. Mora S, Zamproni I, Beccio S, et al. Longitudinal changes of bone mineral density and metabolism in antiretroviral-treated HIV-infected children. J Clin Endocrinol Metab. 2004;89:24-28.
7. Gilsanz V, Roe TF, Mora S, et al. Changes in vertebral bone density in black girls and white girls during childhood and puberty. N Engl J Med. 1991;325:1597-1600.
8. Mora S, Gilsanz V. Establishment of peak bone mass. Endocrinol Metab Clin North Am. 2003;32:39-63.